Trichloroethylene and Parkinson Disease

Neurologic Clinics

Volumn 29, Issue 3, 2011, Pages 657-665

  Zaheer, Fariha ^a   Slevin, John T ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Alpha synuclein; Animal models; Idiopathic Parkinson disease; Mitochondria; Trichloroethylene

Indexed keywords

TRICHLOROETHYLENE;

ALCOHOL INTOLERANCE; CONSCIOUSNESS DISORDER; CRANIAL NEUROPATHY; DIZZINESS; FATIGUE; HEADACHE; HUMAN; IRRITABILITY; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; NERVOUS SYSTEM INFLAMMATION; NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARESTHESIA; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RIGIDITY; SIDE EFFECT; SLEEP DISORDER; TREMOR; VOMITING;

HUMANS; MITOCHONDRIA; PARKINSON DISEASE, SECONDARY; RISK FACTORS; TRICHLOROETHYLENE;

EID: 79960783339     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.05.001     Document Type: Review

References (58)

1. Vance J.M., Ali S., Bradley W.G., et al. Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology 2010, 31(5):598-602.
2. Nagatsu T., Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 2006, 26:781-802.
3. Fall P.A., Fredrikson M., Axelson O., et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 1999, 14(1):28-37.
4. Gorell J.M., Johnson C.C., Rybicki B.A., et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997, 48(3):650-658.
5. Zorzon M., Capus L., Pellegrino A., et al. Familial and environmental risk factors in Parkinson's disease: a case-control study in northeast Italy. Acta Neurol Scand 2002, 105(2):77-82.
6. Langston J.W. The impact of MPTP on Parkinson's disease research: past, present, and future. Parkinson's disease: diagnosis and clinical management 2008, 407-436. Demos, New York. 2nd edition. S.A. Factor, W.J. Weiner (Eds.).
7. Priyadarshi A., Khuder S.A., Schaub E.A., et al. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000, 21(4):435-440.
8. Tanner C.M. Occupational and environmental causes of parkinsonism. Occupational medicine: state of the art reviews 1992, 503-513. Hanley & Belfus, Philadelphia. D. Shusterman, P. Blanc (Eds.).
9. Gorell J.M., Johnson C.C., Rybicki B.A., et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998, 50(5):1346-1350.
10. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
11. Li W., Lesuisse C., Xu Y., et al. Stabilization of alpha-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J Neurosci 2004, 24(33):7400-7409.
12. Manning-Bog A.B., McCormack A.L., Li J., et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002, 277(3):1641-1644.
13. Purisai M.G., McCormack A.L., Langston W.J., et al. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned nonhuman primates. Neurobiol Dis 2005, 20(3):898-906.
14. Zhu J., Chu C.T. Mitochondrial dysfunction in Parkinson's disease. J Alzheimers Dis 2010, 20(Suppl 2):S325-S334.
15. Langston J.W., Ballard P., Tetrud J.W., et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219(4587):979-980.
16. Betarbet R., Sherer T.B., MacKenzie G., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3(12):1301-1306.
17. Perier C., Bove J., Vila M., et al. The rotenone model of Parkinson's disease. Trends Neurosci 2003, 26(7):345-346.
18. Haas R.H., Nasirian F., Nakano K., et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995, 37(6):714-722.
19. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989, 26(6):719-723.
20. Parker W.D., Parks J.K., Swerdlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 2008, 1189:215-218.
21. Mizukawa K., Sora Y.H., Ogawa N. Ultrastructural changes of the substantia nigra, ventral tegmental area and striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Res Commun Chem Pathol Pharmacol 1990, 67(3):307-320.
22. Rapisardi S.C., Warrington V.O., Wilson J.S. Effects of MPTP on the fine structure of neurons in substantia nigra of dogs. Brain Res 1990, 512(1):147-154.
23. Tanaka J., Nakamura H., Honda S., et al. Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey. Acta Neuropathol 1988, 75(4):370-376.
24. Trimmer P.A., Swerdlow R.H., Parks J.K., et al. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol 2000, 162(1):37-50.
25. Song D.D., Shults C.W., Sisk A., et al. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004, 186(2):158-172.
26. Zhu J.H., Horbinski C., Guo F., et al. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol 2007, 170(1):75-86.
27. McCrank E., Rabheru K. Four cases of progressive supranuclear palsy in patients exposed to organic solvents. Can J Psychiatry 1989, 34(9):934-936.
28. Uitti R.J., Snow B.J., Shinotoh H., et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994, 35(5):616-619.
29. Doherty R.E. A history of the production and use of carbon tetrachloride, tetrachloroethylene, trichloroethylene, and 1,1,1-trichloroethane in the United States: part 2-trichloroethylene and 1,1,1-trichloroethane. J Environmental Forensics 2000, 1(2):83-93.
30. Kroschwitz J., Howe-Grant M. Kirk-Othmer Encyclopedia of Chemical Technology 1991, Wiley & Sons, New York.
31. Williams-Johnson M., Eisenmann C.J., Donkin S.G., et al. Toxicological profile for trichloroethylene 1997, Agency for Toxic Substances and Disease Registry, Atlanta (GA).
32. Feldman R.G. Occupational & environmental neurotoxicology 1999, Lippincott-Raven, Philadelphia.
33. Trichloroethylene CoHHRo Assessing the human health risks of trichloroethylene: key scientific issues 2006, The National Academies Press, Washington, DC.
34. Bringmann G., Hille A. Endogenous alkaloids in man, VII: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-a potential chloral-derived indol alkaloid in man. Arch Pharm (Weinheim) 1990, 323(9):567-569.
35. Bringmann G., God R., Feineis D., et al. TaClo as a neurotoxic lead: improved synthesis, stereochemical analysis, and inhibition of the mitochondrial respiratory chain. J Neural Transm Suppl 1995, 46:245-254.
36. Bringmann G., God R., Feineis D., et al. The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. J Neural Transm Suppl 1995, 46:235-244.
37. Kochen W., Kohlmuller D., De Biasi P., et al. The endogeneous formation of highly chlorinated tetrahydro-beta-carbolines as a possible causative mechanism in idiopathic Parkinson's disease. Adv Exp Med Biol 2003, 527:253-263.
38. Rausch W.D., Abdel-mohsen M., Koutsilieri E., et al. Studies of the potentially endogenous toxin TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) in neuronal and glial cell cultures. J Neural Transm Suppl 1995, 46:255-263.
39. Janetzky B., Gille D., Abdel-Mohsen M., et al. Effect of highly halogenated h-carbolines on dopaminergic cells in culture and on mitochondrial respiration. Drug Dev Res 1999, 46:51-56.
40. Bringmann G., Feineis D., God R., et al. Neurotoxic effects on the dopaminergic system induced by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline), a potential mammalian alkaloid: in vivo and in vitro studies. Biog Amines 1996, 12:83-102.
41. Grote C., Clement H.W., Wesemann W., et al. Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) and derivatives. J Neural Transm Suppl 1995, 46:275-281.
42. Riederer P., Foley P., Bringmann G., et al. Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?. Eur J Pharmacol 2002, 442:1-16.
43. Bringmann G., Feineis D., Bruckner R., et al. Synthesis of radiolabelled 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a neurotoxic chloral-derived mammalian alkaloid, and its biodistribution in rats. Eur J Pharm Sci Aug 2006, 28(5):412-422.
44. Drucker G., Raikoff K., Neafsey E.J., et al. Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res 1990, 509(1):125-133.
45. McNaught K.S., Thull U., Carrupt P.A., et al. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Pharmacol 1996, 52(1):29-34.
46. Akundi R.S., Macho A., Munoz E., et al. 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH. J Neurochem 2004, 91(2):263-273.
47. Janetzky B., God R., Bringmann G., et al. 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline, a new inhibitor of complex I. J Neural Transm Suppl 1995, 46:265-273.
48. Haglid K.G., Briving C., Hansson H.A., et al. Trichloroethylene: long-lasting changes in the brain after rehabilitation. Neurotoxicology 1981, 2(4):659-673.
49. Briving C., Jacobson I., Hamberger A., et al. Chronic effects of perchloroethylene and trichloroethylene on the gerbil brain amino acids and glutathione. Neurotoxicology 1986, 7(1):101-108.
50. Vandervort R., Polnkoff P., Dunham-Bush, Inc West Hartford, CN (Health hazard evaluation/toxicity determination report 72-84-31; US NTIS PB-229-627) 1973, National Institute for Occupational Safety and Health, Cincinnati (OH).
51. Trichloroethylene. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans 1979, vol. 20:545-572. International Agency for Research on Cancer, Lyon (France).
52. Dry cleaning, some chlorinated solvents and other industrial chemicals. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans 1979, vol. 63:75-158. International Agency for Research on Cancer, Lyon (France).
53. Guehl D., Bezard E., Dovero S., et al. Trichloroethylene and parkinsonism: a human and experimental observation. Eur J Neurol 1999, 6(5):609-611.
54. Gash D.M., Rutland K., Hudson N.L., et al. Trichloroethylene: parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 2008, 63(2):184-192.
55. Goldman S.M. Trichloroethylene and Parkinson's disease: dissolving the puzzle. Expert Rev Neurother 2010, 10(6):835-837.
56. Liu M., Choi D.Y., Hunter R.L., et al. Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. J Neurochem 2010, 112(3):773-783.
57. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002, 10(2):119-127.
58. Chade A.R., Kasten M., Tanner C.M. Nongenetic causes of Parkinson's disease. J Neural Transm Suppl 2006, (70):147-151.